ARCHES研究:恩扎卢胺联合ADT治疗转移性激素敏感性前列腺癌的III期随机试验
ARCHES是一项跨国双盲III期试验,纳入1150例转移性激素敏感性前列腺癌(mHSPC)患者,随机接受恩扎卢胺(160mg/日)或安慰剂联合雄激素剥夺治疗(ADT)。
要点
- 预设亚组(低/高肿瘤负荷、既往多西他赛)均显示一致获益。
- ≥3级不良事件发生率与安慰剂组相当(24.3% vs 25.6%)。
核心结论
- 恩扎卢胺联合ADT较安慰剂联合ADT显著降低mHSPC患者的影像学进展或死亡风险。
研究设计与样本
- ARCHES为跨国、双盲、III期随机对照试验(NCT02677896),纳入1150例mHSPC男性,1:1随机接受恩扎卢胺160mg/日或安慰剂,均联合ADT,按疾病体积和既往多西他赛分层。
主要发现
- 基于疾病体积和既往多西他赛的预设亚组均显示rPFS显著改善。
- 恩扎卢胺联合ADT显著降低PSA进展、启动新抗肿瘤治疗、首次症状性骨骼事件、去势抵抗和疼痛进展风险。
- ≥3级不良事件发生率恩扎卢胺组24.3% vs 安慰剂组25.6%,无意外不良事件。
临床怎么用
- 恩扎卢胺联合ADT可作为mHSPC患者的治疗选择,包括低肿瘤负荷和/或既往多西他赛治疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: ARCHES (ClinicalTrials.gov identifier: NCT02677896) is a multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume and prior docetaxel chemotherapy. The primary end point was radiographic progression-free survival. RESULTS: As of October 14, 2018, the risk of radiographic progression or death was significantly reduced with enzalutamide plus ADT versus placebo plus ADT (hazard ratio, 0.39; 95% CI, 0.30 to 0.50; P < .001; median not reached v 19.0 months). Similar significant improvements in radiographic progression-free survival were reported in prespecified subgroups on the basis of disease volume and prior docetaxel therapy. Enzalutamide plus ADT significantly reduced the risk of prostate-specific antigen progression, initiation of new antineoplastic therapy, first symptomatic skeletal event, castration resistance, and reduced risk of pain progression. More men achieved an undetectable prostate-specific antigen level and/or an objective response with enzalutamide plus ADT (P < .001). Patients in both treatment groups reported a high baseline level of quality of life, which was maintained over time. Grade 3 or greater adverse events were reported in 24.3% of patients who received enzalutamide plus ADT versus 25.6% of patients who received placebo plus ADT, with no unexpected adverse events. CONCLUSION: Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer.
引用
- Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019. PMID: 31329516. doi:10.1200/JCO.19.00799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。